Valuation : GlaxoSmithKline Pakistan Limited

Market Cap 103B 371M 319M 299M 274M 511M 35.04B 515M 3.54B 1.38B 17.91B 1.39B 1.36B 57.67B P/E 2026 *
9.73x
P/E 2027 * 8.08x
Enterprise Value 103B 371M 319M 299M 274M 511M 35.04B 515M 3.54B 1.38B 17.91B 1.39B 1.36B 57.67B EV / Sales 2026 *
1.49x
EV / Sales 2027 * 1.38x
Free-Float
16.89%
Yield 2026 *
5.58%
Yield 2027 * 6.44%
Sep. 03 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Chief Financial Officer, Effective October 15, 2026 CI
Sep. 03 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Finance Director, Effective October 15, 2026 CI
Aug. 28 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Masood Ahmed Khan to Executive Director, Effective August 28, 2026 CI
Aug. 25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Aug. 25 GlaxoSmithKline Pakistan Limited Interim Cash Dividend for the Half Year Ended June 30, 2026 CI
Aug. 02 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
Aug. 02 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
Jun. 08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
Jun. 08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
May. 31 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
Apr. 30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
Apr. 30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
Apr. 27 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
1 day-0.02%
1 week-5.94%
Current month-3.57%
1 month-7.84%
3 months-6.78%
6 months-4.07%
Current year-17.13%
1 week 321
Extreme 321
341.99
1 month 321
Extreme 321
356
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 69.06
Extreme 69.06
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 2020-02-29
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 72 2020-04-01
Director/Board Member - 2018-12-04
Director/Board Member - 2020-02-29
Change 5-day change 1-year change 3-year change Capi.($)
-0.02%-5.94%-22.12%+361.44% 371M
-1.43%-2.72%+53.81%+104.72% 1,034B
-0.83%+2.97%+54.40%+71.77% 671B
-1.05%+0.76%+20.85%+76.19% 460B
+0.14%-0.45%+29.52%+38.60% 353B
-1.09%+4.98%+25.00%+45.91% 309B
-1.09%+0.40%-1.39%+12.42% 255B
-1.32%+1.26%+56.33%+72.39% 240B
-0.88%+1.15%-17.09%-54.39% 207B
-0.45%+3.16%+33.26%+99.95% 188B
Average -0.80%+0.79%+23.26%+82.90% 371.71B
Weighted average by Cap. -0.99%+1.04%+36.51%+66.55%

Financials

2026 *2027 *
Net sales 68.81B 248M 213M 200M 183M 342M 23.44B 345M 2.37B 922M 11.98B 931M 911M 38.58B 74.58B 269M 231M 217M 199M 371M 25.4B 373M 2.57B 1B 12.98B 1.01B 987M 41.81B
Net income 10.49B 37.8M 32.52M 30.52M 27.92M 52.12M 3.57B 52.53M 361M 141M 1.83B 142M 139M 5.88B 12.42B 44.76M 38.51M 36.14M 33.06M 61.71M 4.23B 62.2M 427M 166M 2.16B 168M 164M 6.96B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
26-09-03 PKR 323.01 -0.02% 122,258
26-09-03 PKR 323.08 -0.80% 118,223
26-09-02 PKR 325.69 -1.92% 146,924
26-09-01 PKR 332.08 -0.86% 646,217
26-08-31 PKR 334.97 -1.12% 344,884
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
323.08PKR
Average target price
510.00PKR
Spread / Average Target
+57.86%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock